CS Paper Radar

HADRec: A Hierarchy-Aware Drug Recommendation Framework by Fusing Molecular Knowledge and Electronic Health Record

Junke Wang, Hongshun Ling, Li Zhang, Jinjing Wu, Tong Shao, Fang Wang, Yuan Gao

cs.LG ·submitted 2026-10-01 03:20 UTC · v1

Abstract

Accurate medication recommendation is central to clinical decision-making, directly determining therapeutic efficacy and patient safety. However, existing methods suffer from two key limitations: drugs are often abstracted as discrete tokens, ignoring their molecular structures and pharmacological mechanisms, and the commonly used "flat" recommendation paradigm fails to leverage the hierarchical logic of the internationally standardized Anatomical Therapeutic Chemical (ATC) classification system. To address these issues, we propose HADRec, a Hierarchy-Aware Drug Recommendation framework that integrates molecular knowledge with electronic health records (EHRs). HADRec employs LLaMA-7B to encode clinical notes for rich patient representations and ChemBERTa to encode drug Simplified Molecular Input Line Entry System strings, building a global molecular knowledge base. A cross-attention mechanism then performs deep multimodal fusion between patient states and drug features. The framework further incorporates a hierarchical predictor and a novel consistency constraint loss to enforce strict adherence to ATC logical dependencies. Extensive experiments on MIMIC-III demonstrate that HADRec achieves state-of-the-art performance across Jaccard, F1, and PR-AUC. External validation on MIMIC-IV confirms strong generalization under distribution shifts, and calibration analysis shows well-calibrated predictive confidence on MIMIC-IV with ECE = 0.04, and Brier = 0.06. Counterfactual evaluation reveals clinically aligned reasoning, disentangling disease-specific treatments from general care. Together, these results establish HADRec as a high-performance, interpretable, and clinically grounded pathway toward safe and reliable AI-driven medication recommendation.

Closest papers

Nearest neighbours by meaning across the whole index.

HCOE: Hyperbolic Clinical Ontology Embeddings from Biomedical Language Models

cs.AI cs.LG ·2026-09-25 ·Yixuan Li, Weihao Li, Ziyang Song
published similarity 0.70
Abstract · Accepted at IEEE BIBM 2026. 7 pages, 3 figures, 4 tables

Biomedical language models (LMs) encode textual semantics but do not explicitly preserve medical code hierarchies. We present Hyperbolic Clinical Ontology Embeddings (HCOE) for hierarchy-aware clinical concept representation. HCOE maps frozen BioBERT embeddings into a Poincare ball, combining parent-side and child-side ontology-guided contrastive learning with coarse-to-fine ontology-path aggregation. It uses International Classification of Diseases (ICD) codes organized by Clinical Classifications Software (CCS) and Anatomical Therapeutic Chemical (ATC) medication hierarchies. Evaluations show that HCOE performs best on ICD/ATC clinical relation prediction and CCS-to-PheCode hierarchy transfer. On the MIMIC-IV dataset, HCOE also achieves the best performance on mortality prediction, readmission prediction, medication recommendation, and rare drug prediction.

0.21

HEM-Med: A Hierarchical Agentic Memory Framework for Safe Multi-Center Medication Recommendation

cs.AI cs.IR ·2026-10-14 ·Min Xiao, Jin Li, Shoujin Wang, Yeguang Zhen, Yishuo Li +1 more
similarity 0.68
Abstract · BIBM 2026

Medication recommendation (MR) is critical for clinical decision support. While existing MR methods are mostly designed for single-center learning, where only one independent hospital is involved, multi-center MR with hospitals of different scales has become increasingly demanding in practice. In multi center settings, abundant data from large medical centers can improve recommendation performance for low-resource centers. Despite a few preliminary attempts on this task, two critical gaps remain. Gap 1: Existing multi-center methods fail to disentangle transferable cross-hospital clinical experience from hospital-specific prescribing patterns, limiting clinical feasibility and physician acceptance. Gap 2: They commonly overlook multi label safety constraints of MR, including drug-drug interaction risks and local formulary feasibility, which are essential for safe real-world deployment. To address these gaps, we propose HEM-Med, a novel hierarchical agentic memory framework for multi-center MR. To address Gap 1, we design a disentangled hierarchical memory module that builds patient-level medication context attribution records and disentangles them into cross hospital experience memory and hospital-specific residual memory. To address Gap 2, we introduce a safety-aware medication set generation module, which integrates dual-level experience retrieval with safety-aware set decoding to produce clinically relevant, safer, and locally adaptive medication recommendations. Experiments on a real-world multi-center eICU dataset show that HEM-Med outperforms representative transfer learning, LLM-based, and MR baselines in terms of both recommendation accuracy and safety.

0.07

RES-MR: Risk-Aware Reasoning for Explainable and Safe Medication Recommendation

cs.LG cs.AIcs.IR ·2026-10-10 ·Cong Wang, Jin Li, Shoujin Wang, Yishuo Li, Huilin Gu +1 more
top venuebenchmarkcode/datahighly cited similarity 0.68
Abstract · 12 pages

Medication recommendations seek to deliver personalized drug combinations based on patients' clinical information, where ensuring transparent decision-making and personalized safety are of paramount importance. However, existing approaches predominantly operate as ``black boxes'', offering limited interpretability and hindering clinician trust. Furthermore, they typically rely on fixed, patient-agnostic safety constraints, neglecting the heterogeneity of risk tolerance across individuals, which poses significant risks to vulnerable populations. To address these gaps, we propose \textbf{RES-MR}, a novel Risk-aware Reasoning framework for Explainable and Safe Medication Recommendation using LLMs. RES-MR follows a two-stage training paradigm: (1) an explainable clinical reasoning distillation stage to elicit diagnostic capabilities by fine-tuning on synthesized reasoning trajectories, grounded in patient-specific knowledge from graph retrieval; and (2) a risk-aware policy optimization stage to dynamically balance therapeutic efficacy with personalized safety. This stage employs disentangled drug factors to construct patient-specific reference prototypes that capture desired therapeutic drug features and risk features to avoid. These prototypes enable risk boundary calibration and guide the model toward safe recommendations via reward shaping and clipping. Extensive experiments on benchmark datasets demonstrate that RES-MR significantly outperforms state-of-the-art baselines in terms of accuracy, safety, and explainability. Our code and data are available at: https://github.com/wangcong2001/RES-MR.

0.78

Knowledge-Enriched Structured EHR Features for 30-Day Hospital Readmission Prediction on MIMIC-IV

cs.LG q-bio.QM ·2026-09-14 ·Mohamad Najafi, Hongyun Fu, Mathias Brochhausen, Jian Wu, Yaohang Li
published similarity 0.67
Abstract · 15 pages, 3 figures. Accepted at SDSC 2026 Mid-Atlantic

Recent approaches to 30-day hospital readmission prediction rely on pre-trained language models applied to discharge summaries. Although these methods achieve strong performance, they depend on the availability of clinical notes, incur substantial computational costs, and yield representations that lack interpretability. We propose a knowledge-enriched feature representation that augments structured Electronic Health Record (EHR) data with four medical knowledge sources: disease ontology mapping, procedure classification, drug ingredient vocabulary, and organ system laboratory aggregation, without using clinical notes. Each feature dimension corresponds to a named clinical concept, yielding a sparse and interpretable patient representation. The approach is evaluated with six classifiers on a MIMIC-IV v2.2 cohort. Under 20-fold cross-validation, the best configuration achieves an AUROC of 0.743. This performance is comparable to that of previously reported methods on this dataset, including both those using only structured data and those incorporating clinical notes, while requiring considerably less computational cost. Interpretability analysis shows that demographics, organ system labs, drug ingredient features, and first-level ontology disease categories drive prediction, while deeper hierarchy levels contribute negligibly. These findings indicate that knowledge-enriched structured features offer a competitive and efficient alternative to embeddings from clinical notes for 30-day readmission prediction.

0.25

DPTM-DT: Dual-Pretrained Transformer Multitask Representation Learning for Drug-Target Prediction

cs.LG cs.AI ·2026-08-28 ·Ge Kong
code/data similarity 0.67
Abstract

Drug-target relation prediction supports candidate screening, drug repositioning, and mechanism analysis. Existing models often use incomplete drug or protein representations, model cross-modal interactions shallowly, or train affinity regression and interaction classification separately, although these tasks describe closely related views of the same drug-target pair. This paper presents DPTM-DT, a dual-pretrained Transformer framework for multitask drug-target prediction. DPTM-DT combines GROVER molecular graph embeddings, ESM protein language-model embeddings, and CTD physicochemical descriptors, then exchanges drug-target information through bidirectional cross-modal attention. A shared pair representation is used for continuous affinity regression, high-affinity binary classification, and six-level affinity classification. Experiments on Davis and KIBA cover random 80/20 and DeepDTA-style standard splits. On the random 80/20 split, DPTM-DT achieves MSE/CI values of 0.193/0.917 on Davis and 0.120/0.918 on KIBA. It also reports binary AUPR/MCC values of 0.727/0.654 and 0.798/0.689, and six-class Macro-F1/Top-2 values of 0.800/0.932 and 0.815/0.962 on Davis and KIBA, respectively. Across the reported regression, binary classification, and multiclass classification settings, DPTM-DT achieves the best overall performance among the compared methods. Results under the standard split show the same relative trend. Ablations indicate that dual target representation, gated fusion, and cross-modal attention each contribute to the final performance. Code and supplementary materials are available at: anonymous.4open.science/r/DPCM-DT-74E0.

0.26

Drug-Target Interaction Prediction via Hierarchical Sequential Cross-Attention over Chemical and Protein Language Models

cs.LG cs.AI ·2026-09-28 ·Khadidja Henni, Hamza Abdelali, Abdelkrim Aries, Neila Mezghani, Brigitte Vannier +2 more
similarity 0.67
Abstract

Predicting Drug-Target Interactions~(DTIs) is a central task in computational drug discovery, with direct applications in virtual screening, drug repurposing, and therapeutic candidate prioritization. Although recent deep learning methods have improved DTI prediction, many sequence-based models still process drugs and proteins independently and only combine their representations at a late prediction stage. This limits their ability to explicitly model cross-molecular dependencies between chemical substructures and protein sequence regions. In this paper, we propose a sequence-only DTI prediction architecture that combines two pre-trained language models, ChemBERTa for drug SMILES strings and ESM-2 for protein amino acid sequences, with a hierarchical interaction module. The proposed model first extracts contextual representations using pre-trained encoders, then applies 1D convolutional layers to condense local sequence patterns, followed by a sequential bidirectional cross-attention mechanism inspired by the induced-fit view of molecular recognition. Finally, attention-based pooling constructs fixed-size interaction-aware vectors for binary prediction. Experiments on BIOSNAP, Davis, and BindingDB show that the proposed model achieves the best performance on BIOSNAP, matches the best AUROC on Davis, and remains competitive on BindingDB while using only 25.2 million trainable parameters. Ablation results confirm the contribution of both the CNN and cross-attention modules, and cold-start experiments indicate promising generalization to unseen proteins and drugs.

0.12

HierDTA: Hierarchical Structure-Aware Representation Learning for Drug--Target Affinity Prediction

cs.LG cs.AI ·2026-10-19 ·Huangchao Xu, Baohua Zhang, Qian Liu, Zhong Jin, Yi Du
published similarity 0.66
Abstract · 20 pages, 7 figures

Drug--target affinity (DTA) prediction plays an important role in computer-aided drug discovery, where reliable computational models can help prioritize compound--protein pairs before experimental validation. A key challenge in DTA prediction is to effectively mine multi-level molecular information from drug structures while accurately modeling the binding-site environment of target proteins. To address these issues, we introduce HierDTA, a hierarchical structure-aware framework for DTA prediction. \textcolor{black}{HierDTA represents each drug as an atom--motif heterogeneous graph and introduces an augmentation module that propagates functional-motif semantics to the corresponding atoms. For proteins, kinase-domain structures are converted into residue interaction graphs. The resulting atom and residue representations are integrated using cross-attention to capture pair-specific relationships, while molecule fingerprints and pretrained ESM-2 embeddings provide complementary global information. Compared with state-of-the-art methods, HierDTA achieves superior performance on the Davis dataset across all metrics and attains the highest \(r_m^2\) of 0.791 on KIBA. It also exhibits strong generalization under cold-start settings, particularly on KIBA, where MSE is reduced by 21.7\% in the unseen-protein scenario. Ablation study and interpretability analysis supported the contributions of the hierarchical augmentation and interaction components.} Case studies further showed that HierDTA provided early enrichment of candidate bioactive compounds. These results indicate that HierDTA is an effective framework for affinity prediction and target-specific virtual screening.

0.31

Clinical Evidence-Guided Residual Learning for Medication Recommendation with Dynamic DDI Regularization

cs.LG cs.IR ·2026-11-07 ·Zesheng Li, Chengchang Pan, Honggang Qi
code/data similarity 0.66
Abstract · 13 pages, 6 figures, 8 tables. Supplementary PDF and detailed result tables are included as ancillary files. Code: https://github.com/LIZESH…

Medication recommendation must combine patient-specific treatment evidence with the interaction structure of a prescription. The central challenge is to determine which evidence supports each medication and how strongly to regularize interactions while preserving predictive quality. We propose EviDrug, a clinical evidence-guided residual learning framework. Its clinical-memory backbone integrates a self-trained visit-aware encoder, training-case memory and one medication-set interaction block to establish a patient-specific prescription. A gated refinement head combines the backbone states with clinical associations and history-conditioned medication identities through bounded logit corrections. Drug-drug interaction (DDI) feedback adapts regularization strength using training-query predictions. Across MIMIC-IV, NWICU and SICdb, EviDrug leads twelve published-method baselines in AP, F1 and Jaccard, improving AP by 2.26, 2.06 and 1.71 percentage points over the strongest comparator. These gains come at lower parameter and runtime costs than MetaDrug. Matched controls demonstrate DDI reductions with stable predictive quality. Code is available at https://github.com/LIZESHENG13/EviDrug.

0.28